CLARITY PHARMACEUTICALS Mediaroom

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"),...

2026-04-14 21:02 2095

Co-PSMA data published in the European Urology journal

SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"),...

2026-03-31 20:58 2349

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"),...

2026-03-25 21:01 4273

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

HIGHLIGHTS * Oral presentation on key results from the Co-PSMA (NCT06907641

2026-03-17 21:01 4864

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

Registrational Phase III AMPLIFY trial: Target number of participants achieved

SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"),...

2026-03-10 21:02 5215

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT)...

2026-02-16 22:03 9170

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SE...

2026-01-15 22:02 6701

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-12-24 22:02 4421

Clarity signs copper-67 Supply Agreement with Nusano

SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-10-16 21:04 3788

Co-PSMA trial achieves primary endpoint

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-10-14 21:03 3588

Co-PSMA trial: Recruitment successfully completed

SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-07-17 21:01 3892

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Highlights * Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for64...

2025-06-17 21:04 4061

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

Highlights * Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64 Cu-SAR-...

2025-06-13 21:01 3712

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

HIGHLIGHTS * Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SA...

2025-06-05 21:01 3082

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

HIGHLIGHTS * Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and...

2025-03-05 21:44 2948

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), ...

2025-02-19 22:09 3045

Latest News